#BestACR20Tweets RT @doctorRBC : Mavrilimumab efficacious in maintaining disease remission in GCA pts. Phase 2 trial (n=70) Disease flare 19% in tx vs. 46% in PBO at 26wk Sustained remission 83% vs. 50% in PBO Similar AE in both groups Abs#L06 https://t.co/fsZxZVmDIu" https://t.co/j17naatAxX